Concord Drugs Profit & Loss Annual

BSE: 538965 | NSE: - | ISIN: INE858L01010 | Sector: Biotechnology & Drugs

34.75 -1.25 (-3.47%)Updated : 26 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Revenue	44.92	52.08	58.96	51.36
Total Revenue	44.92	52.08	58.96	51.36
Costof Revenue Total	33.25	41.00	42.10	42.18
Gross Profit	11.67	11.08	16.86	9.18
Selling/ General/ Admin Expenses Total	6.08	4.92	4.89	3.76
Depreciation/ Amortization	1.56	1.63	1.76	1.37
Other Operating Expenses Total	1.55	1.59	6.37	2.20
Total Operating Expense	42.44	49.13	55.13	45.74
Operating Income	2.49	2.95	3.83	5.62
Interest Inc( Exp) Net- Non- Op Total	-18.68	-16.34	-14.13	-12.45
Other Net	0.01	-0.06	-0.17	-0.08
Net Income Before Taxes	0.63	1.25	2.25	4.29
Provisionfor Income Taxes	0.16	0.26	0.65	1.01
Net Income After Taxes	0.47	0.99	1.59	3.28
Net Income Before Extra Items	0.47	0.99	1.59	3.28
Net Income	0.47	0.99	1.59	3.28
Income Availableto Com Excl Extra Ord	0.47	0.99	1.59	3.28
Income Availableto Com Incl Extra Ord	0.47	0.99	1.59	3.28
Diluted Net Income	0.47	0.99	1.59	3.28
Diluted Weighted Average Shares	1.01	0.93	0.87	0.87
Diluted EPS Excluding Extra Ord Items	0.47	1.06	1.82	3.75
Diluted Normalized EPS	0.47	1.06	1.82	0.46
Unusual Expense( Income)	-	0.00	0.00	-3.76